Organon & Co. (NYSE:OGN) Shares Bought by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV raised its holdings in shares of Organon & Co. (NYSE:OGN) by 1.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,086 shares of the company’s stock after acquiring an additional 546 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Organon & Co. were worth $674,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Versant Capital Management Inc lifted its position in Organon & Co. by 200.2% during the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock valued at $25,000 after purchasing an additional 805 shares during the period. Fidelis Capital Partners LLC acquired a new position in shares of Organon & Co. in the 1st quarter valued at about $43,000. Tompkins Financial Corp boosted its stake in shares of Organon & Co. by 450.7% in the first quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock worth $45,000 after buying an additional 1,974 shares during the last quarter. Atlas Capital Advisors LLC grew its holdings in Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after acquiring an additional 2,147 shares during the period. Finally, Hexagon Capital Partners LLC raised its position in Organon & Co. by 123.9% during the first quarter. Hexagon Capital Partners LLC now owns 2,628 shares of the company’s stock valued at $49,000 after acquiring an additional 1,454 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on OGN. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded shares of Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price target for the stock from $18.00 to $20.00 in a report on Friday, September 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $21.00.

Organon & Co. Stock Up 0.6 %

Shares of OGN opened at $19.15 on Friday. The firm has a market cap of $4.93 billion, a P/E ratio of 4.68, a PEG ratio of 0.87 and a beta of 0.85. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $23.10. The stock’s 50 day moving average is $20.88 and its two-hundred day moving average is $20.12. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. The firm had revenue of $1.61 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. During the same quarter last year, the company earned $1.31 EPS. Analysts predict that Organon & Co. will post 4.14 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Investors of record on Friday, August 16th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 5.85%. The ex-dividend date of this dividend was Friday, August 16th. Organon & Co.’s payout ratio is 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.